ES2054696T3 - Agente viral de la hepatitis nanb, antigen y reactivo inmunologico. - Google Patents

Agente viral de la hepatitis nanb, antigen y reactivo inmunologico.

Info

Publication number
ES2054696T3
ES2054696T3 ES87402519T ES87402519T ES2054696T3 ES 2054696 T3 ES2054696 T3 ES 2054696T3 ES 87402519 T ES87402519 T ES 87402519T ES 87402519 T ES87402519 T ES 87402519T ES 2054696 T3 ES2054696 T3 ES 2054696T3
Authority
ES
Spain
Prior art keywords
antigen
viral
nanb
viral agent
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87402519T
Other languages
English (en)
Inventor
Jacques Pillot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur de Lille
Original Assignee
Institut Pasteur de Lille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR8615625A external-priority patent/FR2606515B1/fr
Priority claimed from FR8701738A external-priority patent/FR2609807B2/fr
Application filed by Institut Pasteur de Lille filed Critical Institut Pasteur de Lille
Application granted granted Critical
Publication of ES2054696T3 publication Critical patent/ES2054696T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

NUEVO AGENTE VIRUL PURIFICADO, IMPLICADO EN LA HEPATITIS VIRAL NO - A NO B, EPIDEMIA, ESPORADICA O POST - TRANSFUSIONAL, DEFINIDO EL PERFIL DE REPARTICION DE SU ACTIVIDAD ANTIGENA, QUE COMPORT6A AL MENOS UNA BANDA DE DENSIDAD 1,28 - 1,32 G/CM3 Y/O AL MENOS UNA BANDA DE DENSIDAD DE 1,17 - 1,19 G/CM3, Y EL ANTIGENO ASOCIADO A ESTE AGENTE VIRAL. PROCEDIMIENTO PARA AISLAR DICHO AGENTE VIRAL Y EL ANTIGENO QUE LE ES ASOCIADO, UTILIZACION DEL AGENTE VIRAL MIENTRAS SE REACTIVA EL DIAGNOSTICO. PROCEDIMIENTO DE DETECCION DEL ANTIGENO NO - A NO - B PRESENTE EN LAS HECES DE LOS PACIENTES ATENDIDOS DE HEPATITS VIRAL NO - A NO - B. REACTIVO INMUNOLOGICO PARA LA DETECCION DE LA HEPATITIS VIRAL NANB, EPIDEMICA, ESPORADICA O POST - TRANSFERENCIAL Y PROCESO DE AISLAMIENTO DE ANTICUERPOS ANTI - NANB APTOS PARA SER UTILIZADOS MIENTRAS LOS REACTIVOS INMUNOLOGICOS, APLICACION DE DICHOS ANTICUERPOS ANTI - NANB EN EL DIAGNOSTICO DE LA HEPATITIS VIRAL NANB EPIDEMICA, ESPORADICA O POST TRANSFERENCIAL Y EN EL TRANSCURSO DE LOS AGENTES TERAPEUTICOS.
ES87402519T 1986-11-07 1987-11-06 Agente viral de la hepatitis nanb, antigen y reactivo inmunologico. Expired - Lifetime ES2054696T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8615625A FR2606515B1 (fr) 1986-11-07 1986-11-07 Procede pour l'isolement d'un nouvel agent viral et de l'antigene qui lui est associe, agent viral et antigene obtenus par ce procede et procede de detection dudit antigene a l'aide d'un reactif immunologique approprie
FR8701738A FR2609807B2 (fr) 1987-02-11 1987-02-11 Reactifs immunologiques pour la detection de l'hepatite virale nanb, leurs procedes de preparation et leurs applications dans des procedes de detection de l'hepatite virale nanb et en tant qu'agents therapeutiques

Publications (1)

Publication Number Publication Date
ES2054696T3 true ES2054696T3 (es) 1994-08-16

Family

ID=26225574

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87402519T Expired - Lifetime ES2054696T3 (es) 1986-11-07 1987-11-06 Agente viral de la hepatitis nanb, antigen y reactivo inmunologico.

Country Status (7)

Country Link
EP (1) EP0277437B1 (es)
JP (1) JP2602517B2 (es)
AU (1) AU611402B2 (es)
DE (1) DE3784484T2 (es)
ES (1) ES2054696T3 (es)
NZ (1) NZ222465A (es)
WO (1) WO1988003410A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698390A (en) * 1987-11-18 1997-12-16 Chiron Corporation Hepatitis C immunoassays
US5712088A (en) * 1987-11-18 1998-01-27 Chiron Corporation Methods for detecting Hepatitis C virus using polynucleotides specific for same
YU48038B (sh) * 1987-11-18 1996-10-18 Chiron Corp. Postupak za dijagnostiku ne-a, ne-v hepatitisa
US5714596A (en) * 1987-11-18 1998-02-03 Chiron Corporation NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus
US6171782B1 (en) 1987-11-18 2001-01-09 Chiron Corporation Antibody compositions to HCV and uses thereof
US5350671A (en) * 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
WO1989004669A1 (en) * 1987-11-18 1989-06-01 Chiron Corporation Nanbv diagnostics and vaccines
US6861212B1 (en) 1987-11-18 2005-03-01 Chiron Corporation NANBV diagnostics and vaccines
US5789559A (en) * 1988-06-17 1998-08-04 Genelabs Technologies, Inc. DNA sequences of enterically transmitted non-A/non-B hepatitis viral agent
US5824649A (en) * 1988-06-17 1998-10-20 Genelabs Technologies, Inc. DNA sequences of enterically transmitted non-A/non-B hepatitis viral agent and characteristic epitopes thereof
DE3837616A1 (de) * 1988-11-05 1990-05-10 Behringwerke Ag Einschritt-immuntest zur bestimmung von antigen-spezifischen antikoerpern aller immunglobulin-klassen und dazu geeignetes mittel
US6027729A (en) * 1989-04-20 2000-02-22 Chiron Corporation NANBV Diagnostics and vaccines
DK298190A (da) * 1989-12-18 1991-06-19 Wellcome Found Viralt middel
US7166287B1 (en) 1989-12-18 2007-01-23 Glaxo Wellcome Inc. Viral agent
EP0447984A1 (en) * 1990-03-20 1991-09-25 Abbott Laboratories Hyperimmune globulin against hepatitis C virus and method for making same
JP3473700B2 (ja) * 1991-08-26 2003-12-08 ボーリンガー・インゲレイム・ヴェトメディカ・インコーポレーテッド Ｓｉｒｓワクチンおよびｓｉｒｓ診断方法
US5846805A (en) 1991-08-26 1998-12-08 Boehringer Ingelheim Animal Health, Inc. Culture of swine infertility and respiratory syndrome virus in simian cells
US6080570A (en) * 1991-08-26 2000-06-27 Boehringer Ingelheim Vetmedica, Inc. Method of producing a vaccine for Swine Infertility and Respiratory Syndrome
US6982160B2 (en) 1991-08-26 2006-01-03 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions that include SIRS virus
AU2696792A (en) * 1991-09-16 1993-04-27 David A Benfield Vaccine for mystery swine disease and method for diagnosis thereof
EP0839912A1 (en) 1996-10-30 1998-05-06 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
CA2366072C (en) 1999-03-08 2007-07-10 Id-Lelystad, Instituut Voor Dierhouderij En Diergezondheid B.V. Prrsv vaccines
AU4482200A (en) 1999-04-22 2000-11-10 United States Department Of Agriculture Porcine reproductive and respiratory syndrome vaccine, based on isolate ja-142
EP1781327A4 (en) 2004-06-18 2009-02-25 Univ Minnesota IDENTIFICATION OF VIRAL INFECTED AND VACCINATED ORGANISMS
US7632636B2 (en) 2004-09-21 2009-12-15 Boehringer Ingelheim Vetmedica, Inc. Porcine reproductive and respiratory syndrome isolates and methods of use
BRPI0611594B1 (pt) 2005-06-24 2021-11-30 Regents Of The University Of Minnesota Polinucleotídeos infecciosos isolados e clones infecciosos
AR078253A1 (es) 2009-09-02 2011-10-26 Boehringer Ingelheim Vetmed Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad
ES2692809T3 (es) 2011-02-17 2018-12-05 Boehringer Ingelheim Vetmedica Gmbh Nueva cepa del PRRSV europea
SG192821A1 (en) 2011-02-17 2013-09-30 Boehringer Ingelheim Vetmed Commercial scale process for production of prrsv
WO2013017570A1 (en) 2011-07-29 2013-02-07 Boehringer Ingelheim Vetmedica Gmbh Novel prrs virus inducing type i interferon in susceptible cells
US9187731B2 (en) 2011-07-29 2015-11-17 Boehringer Ingelheim Vetmedica Gmbh PRRS virus inducing type I interferon in susceptible cells
WO2014150822A2 (en) 2013-03-15 2014-09-25 Boehringer Ingelheim Vetmedica, Inc. Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use
CA2930042C (en) 2013-12-20 2022-06-21 Boehringer Ingelheim Vetmedica Gmbh Prrs virus variant, european prrs virus cdna clone, and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356164A (en) * 1979-05-21 1982-10-26 Govt. of the U.S., as represented by the Secretary, Dept. of Health & Human Services Detection of non-A, non-B hepatitis associated antigen
AU540153B2 (en) * 1979-05-21 1984-11-01 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Detection of non-a, non-b hepatitis associated antigen
GB2108527B (en) * 1981-02-11 1984-10-24 Connaught Lab Non-a non-b hepatitis virus
US4542016A (en) * 1981-03-27 1985-09-17 Institut Merieux Non-a non-b hepatitis surface antigen useful for the preparation of vaccines and methods of use
FR2502154A1 (fr) * 1981-03-30 1982-09-24 Trepo Christian Procede de preparation d'antigenes de l'hepatite virale nanb, et application a la realisation d'un reactif permettant le diagnostic et le pronostic des infections provoquees par les virus des hepatites virales
JPS57198867A (en) * 1981-06-02 1982-12-06 Eisai Co Ltd Non-a, non-b hepatitis related antigen and diagnostic therefor
JPS58753A (ja) * 1981-06-25 1983-01-05 Eisai Co Ltd 非ａ非ｂ型肝炎関連抗体および検出試薬
JPS58183629A (ja) * 1982-04-21 1983-10-26 Eisai Co Ltd 非ａ非ｂ型肝炎関連モノクロナ−ル抗体および診断薬
EP0093438B1 (en) * 1982-05-05 1988-07-20 Louisiana State University and Agricultural and Mechanical College Non-a, non-b hepatitis antigen
FR2597606B1 (fr) * 1986-04-16 1989-10-06 Pasteur Institut Nouveau reactif pour la detection d'hepatites virales non a non b et procede de diagnostic de telles hepatites par voie immunoenzymatique

Also Published As

Publication number Publication date
JPH01501205A (ja) 1989-04-27
AU8273487A (en) 1988-06-01
AU611402B2 (en) 1991-06-13
EP0277437B1 (fr) 1993-03-03
NZ222465A (en) 1992-11-25
WO1988003410A1 (fr) 1988-05-19
EP0277437A1 (fr) 1988-08-10
DE3784484D1 (de) 1993-04-08
JP2602517B2 (ja) 1997-04-23
DE3784484T2 (de) 1993-07-01

Similar Documents

Publication Publication Date Title
ES2054696T3 (es) Agente viral de la hepatitis nanb, antigen y reactivo inmunologico.
ES2130121T3 (es) Antigeno intra-acrosomico de esperma humano para uso en una vacuna anticonceptiva.
DK614987A (da) Syntetiske htlv-iii peptider, praeparater og anvendelser deraf
DK0610250T3 (da) Vaccine med porcint reproduktivt respiratorisk syndrom og diagnose heraf
DE69327307D1 (de) Herstellung von antigenen und impfstoffen vom mysterie-disease-virus, antigene und erworbene impfstoffe zur verhinderung dieser krankheit
ES2110411T3 (es) Metodos para cultivar el virus de la hepatitis c (hcv) en lineas celulares de linfocitos b o t.
ATE17320T1 (de) Impfstoff, therapie gegen nicht-a nicht-b virale hepatitis und verfahren zur herstellung desselben.
BE852416A (fr) Procede de purification et d'isolation du virus de l'hepatite en vue de l'utiliser dans la preparation de vaccins
DK388384D0 (da) Monoklone antistoffer med specifitet for membran-associerede antigene, deres fremstilling og anvendelse
ES2065863T3 (es) Analisis para la deteccion de virus de la hepatitis c.
IL68201A0 (en) Peptides with the specificity of foot and mouth disease viral antigens and compositions and methods for treating animals using the same
ES2050114T3 (es) Anticuerpos monoclonales humanos para el virus asociado a la linfoadenopatia.
KR890700662A (ko) 바이러스 항원과 그의 제조방법 및 진단과 치료를 목적으로 하는 사용방법
DE69333076D1 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
DK372780A (da) Fremgangsmaade til propagering af humant hepatitis a virus
DE3750225D1 (de) Herstellung und verwendung von anti-helminthischen wirkstoffen und schutzantigenen.
ES2100893T3 (es) Procedimiento de preparacion de una vacuna o de un agente toxico.
ES2056075T3 (es) Anticuerpos monoclonales para regiones especificas antigenicas del virus de inmunodeficiencia humana y procedimientos para su uso.
SE7707889L (sv) Haptoglobinpreparat
ES2118129T3 (es) Anticuerpos monoclonales contra las regiones de cubierta putativas del virus vhc y procedimientos de utilizacion de estos.
FI92716C (fi) Uudet monoklonaaliset vasta-aineet IFN-omegalle, niiden valmistusmenetelmät ja niiden käyttö IFN-omegan puhdistamiseen ja osoittamiseen
ES2132115T3 (es) Anticuerpos monoclonales contra el virus de la hepatitis c y su procedimiento de utilizacion.
Henle et al. Cross-reactions among γ-globulins of various species in indirect immunofluorescence
BR9307176A (pt) Métodos para identificação de um paciente contaminado com hiv para determinar a eficácia do tratamento de um paciente humano infectado com hiv e processo para identificar os indivíduos contaminados com hiv
ES2155436T3 (es) Proteinas recombinantes con la reactividad inmunologica del antigeno e del virus de la hepatitis b (hbeag), procedimiento para su preparacion y su utilizacion en analisis inmunologicos y en vacunas.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 277437

Country of ref document: ES